UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment

PloS one, 2015-02, Vol.10 (2), p.e0118346-e0118346

2015

Volltextzugriff (PDF)

CDX2 expression and perioperative patient serum affects the adhesion properties of cultured colon cancer cells

BMC cancer, 2020-05, Vol.20 (1), p.426-426, Article 426

2020

Volltextzugriff (PDF)

Assessment of perioperative stress in colorectal cancer by use of in vitro cell models: a systematic review

PeerJ (San Francisco, CA), 2017-11, Vol.5, p.e4033-e4033, Article e4033

2017

Volltextzugriff (PDF)

Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients

Clinical cancer research, 2009-02, Vol.15 (4), p.1487-1495

2009

Volltextzugriff (PDF)

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant

Cancer letters, 2014-03, Vol.344 (1), p.90-100

2014

Volltextzugriff (PDF)

Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients

Clinical cancer research, 2007-03, Vol.13 (5), p.1405-1411

2007

Volltextzugriff (PDF)

A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells

Bone (New York, N.Y.), 2004-11, Vol.35 (5), p.1107-1119

2004

Volltextzugriff (PDF)

Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH

Histopathology, 2010-01, Vol.56 (2), p.203-211

2010

Volltextzugriff (PDF)

Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption

Bone (New York, N.Y.), 2004, Vol.34 (1), p.37-47

2004

Volltextzugriff (PDF)

Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen Activation

Experimental cell research, 1997-05, Vol.232 (2), p.420-429

1997

Volltextzugriff (PDF)

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer

Clinical cancer research, 2016-11, Vol.22 (22), p.5514-5526

2016

Volltextzugriff (PDF)

Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer

Histopathology, 2012-01, Vol.60 (2), p.369-371

2012

Volltextzugriff (PDF)

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D 3

The Journal of steroid biochemistry and molecular biology, 2018-03, Vol.177, p.171

2018

Volltextzugriff (PDF)

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

The Journal of pathology, 2005-10, Vol.207 (2), p.139-146

2005

Volltextzugriff (PDF)

Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer

Acta oncologica, 2018-01, Vol.57 (1), p.67-73

2018

Volltextzugriff (PDF)

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3

The Journal of steroid biochemistry and molecular biology, 2018-03, Vol.177, p.171-178

2018

Volltextzugriff (PDF)

The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines

International journal of oncology, 2014-07, Vol.45 (1), p.393-400

2014

Volltextzugriff (PDF)

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

BMC cancer, 2015-04, Vol.15 (1), p.239-239, Article 239

2015

Volltextzugriff (PDF)

A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis

Acta oncologica, 2017-09, Vol.56 (9), p.1161-1167

2017

Volltextzugriff (PDF)

Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F

Thrombosis and haemostasis, 2000-05, Vol.83 (5), p.742

2000

Volltextzugriff (PDF)

Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response

Oncotarget, 2016-06, Vol.7 (25), p.38408-38426

2016

Volltextzugriff (PDF)

Transforming Growth Factor-β Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression

The Journal of biological chemistry, 2003-11, Vol.278 (45), p.44975-44987

2003

Volltextzugriff (PDF)

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

Breast cancer research and treatment, 2010-06, Vol.121 (3), p.601-613

2010

Volltextzugriff (PDF)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

NPJ breast cancer, 2021-01, Vol.7 (1), p.2-2, Article 2

2021

Volltextzugriff (PDF)

Bad expression predicts outcome in patients treated with tamoxifen

Breast cancer research and treatment, 2007-04, Vol.102 (2), p.173-179

2007

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment

CDX2 expression and perioperative patient serum affects the adhesion properties of cultured colon cancer cells

Assessment of perioperative stress in colorectal cancer by use of in vitro cell models: a systematic review

Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant

Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients

A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells

Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH

Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption

Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen Activation

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer

Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D 3

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3

The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis

Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F

Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response

Transforming Growth Factor-β Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

Bad expression predicts outcome in patients treated with tamoxifen

Suchergebnisse filtern